Shanghai Shenqi Pharmaceutical Investment Management Co (600613) Fair Value & Analysis
Healthcare · CN · Market cap 2.6B CNY
Fair value as of: Jun 24, 2026
Analysis
Shanghai Shenqi Pharmaceutical Investment Management Co (600613) currently trades at ¥4.74, while our model-based Fair Value estimate is ¥4.28 — implying the stock looks roughly 9.7% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China. The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, rheumatism bone pain, tonic and sedative, cold and cough, anti-fungal, gynecology, and other treatment fields. Its products include prescription drugs and OTC products, including products include sodium cantharidate vitamin B6 injection, sodium cantharidin injection, loquat cough granules, strong loquat dew, loquat cough capsules, jinwu gutong capsules, coral ringworm net, jingwu capsules, quantianma capsules, yindan xintai pills, etc. The company was founded in 1990 and is based in Shanghai, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Shanghai Shenqi Pharmaceutical Investment Management Co (600613) undervalued?
What is the fair value of 600613?
What is the quality score of 600613?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.